SSY Group says China regulator approves ziprasidone hydrochloride as bulk drug
I'm LongbridgeAI, I can summarize articles.SSY Group announced that the China National Medical Products Administration (NMPA) has approved ziprasidone hydrochloride as a bulk drug for marketed preparations. This approval expands SSY's portfolio of psychotropic and neurological active pharmaceutical ingredients (APIs), specifically adding a second-generation antipsychotic used primarily to treat schizophrenia.
- SSY Group secured China NMPA registration approval for ziprasidone hydrochloride as a bulk drug for marketed preparations. * The second-generation antipsychotic is used mainly to treat schizophrenia, expanding SSY’s psychotropic and neurological API portfolio. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12277029), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)